Former Theranos CEO Elizabeth Holmes leaves federal courtroom in San Jose, Calif., Friday, March 17, 2023.

Jeff Chiu/AP

cover caption

toggle caption

Jeff Chiu/AP

Former Theranos CEO Elizabeth Holmes leaves federal courtroom in San Jose, Calif., Friday, March 17, 2023.

Jeff Chiu/AP

A California federal decide has denied Theranos founder Elizabeth Holmes’ request to stay free on bail as the previous chief of the medical expertise startup tries to attraction her conviction for wire fraud, according to court documents filed Monday.

In January 2022, Holmes was convicted of three counts of wire fraud and one rely of conspiracy to commit wire fraud after a jury discovered that she defrauded traders out of greater than $100 million over a blood-testing gadget that didn’t work as marketed.

She was later sentenced to 11 years in jail and three years of supervised launch. Holmes filed for an attraction in December 2022.

A courtroom might enable a launch throughout an attraction if the defendant is just not seen as a flight danger or risk to the neighborhood, the request is not used to delay the defendant going to jail or the attraction raises a considerable query of details or regulation.

The U.S. District Court Northern District of California dominated that whereas Holmes is just not seen as a hazard to the neighborhood or flight danger, she has not efficiently introduced new proof. In her attraction, Holmes argued she didn’t promote a defective product, although the courtroom dominated “these disputes do not directly pertain to the conduct for which Ms. Holmes was convicted.”

“Ms. Holmes’s misrepresentations to Theranos investors involved more than just whether Theranos technology ‘worked as promised,'” the courtroom’s opinion says. “Ms. Holmes had also made several misrepresentations…such as those regarding the company’s financial status, reliance on third-party and commercially available devices, partnership with Walgreens, and validation by pharmaceutical companies.”

Holmes, 39, based Theranos when she was an undergraduate pupil at Stanford University. The firm promised that its expertise may display screen sufferers for illnesses with a pattern from a single finger prick of blood fairly than a full blood draw.

Holmes attracted almost $1 billion in investments even because the expertise didn’t work as claimed. Its outcomes had been typically defective, and the corporate ceaselessly relied on commercially obtainable blood analyzer machines to conduct its assessments.